TMS for Complex Regional Pain Syndrome
Transcranial Magnetic Stimulation (TMS) for Complex Regional Pain Syndrome (CRPS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Omar Altirkawi
- Phone Number: (650) 497-0485
- Email: omar97@stanford.edu
Study Locations
-
-
California
-
Redwood City, California, United States, 94043
- Recruiting
- Stanford Pain Management Center
-
Contact:
- Birute Gedrimaite
- Phone Number: 650-497-0485
- Email: birute@stanford.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-70
- Diagnosis of CRPS (complex regional pain syndrome) for at least 3 months
- Average pain level reported on Numerical Rating Scale meets entry criteria
- Ability to perform the experimental task and procedures.
Exclusion Criteria:
- MRI contraindication (metal implants or devices, claustrophobia)
- TMS Contraindication (eg metal implant or devices near the site of stimulation)
- History of epilepsy
- History of a psychological or psychiatric disorder that would interfere with study procedures, at the discretion of the researcher.
- Neurologic illness that would interfere with brain integrity
- Current medical condition or medication use that would interfere with study procedures or data integrity, at the discretion of the researcher.
- Currently pregnant or planning to become pregnant.
- On going legal action or disability claim.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Active Treatment
Participants will receive active TMS in the target area once daily for two days
|
The Magventure TMS stimulator will be used to perform intermittent theta burst followed by high frequency Transcranial Magnetic Stimulation (TMS).
|
|
Sham Comparator: Sham Treatment
Participants will receive active TMS in a non-target area once daily for two days
|
The Magventure TMS stimulator will be used to perform intermittent theta burst followed by high frequency Transcranial Magnetic Stimulation (TMS).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Pain
Time Frame: 1 week follow-up compared to baseline
|
Decrease in CRPS-related Pain Ratings
|
1 week follow-up compared to baseline
|
|
Duration of Pain Relief
Time Frame: Duration from last treatment until pain returns - up to an estimate of 6 months
|
Duration of decreased CRPS-related pain ratings, measured as a length of time until pain returns for two consecutive weeks
|
Duration from last treatment until pain returns - up to an estimate of 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Pain-related Symptomology
Time Frame: Duration from last treatment until pain returns - up to an estimate of 6 months
|
Decreases in Pain-related Symptomology (i.e., cognitive, emotional and physical)
|
Duration from last treatment until pain returns - up to an estimate of 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 25894-3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.